Searched for
USTEKINUMAB
Biocon in very unique position globally as a biosimilars leader: Kiran Mazumdar-ShawBiocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to accelerate gr...- Biocon gets Health Canada nod for biosimilars Yesintek, Yesintek IVBiocon Biologics has made strides in the healthcare sector by obtaining Health Canada’s approval for Yesintek and Yesintek IV, its latest a...
- Biocon plans $150-million capex in two yearsBiocon plans a $150 million capital expenditure, allocating $100 million to biologics, primarily enhancing Malaysian capacities, and $50 mi...
- Biocon Biologics secures multiple market access agreements in US for YesintekBiocon Biologics' Yesintek, a biosimilar to Stelara, has secured significant market access in the US, covering over 100 million lives. Mult...
- Biocon shares in focus after successful results of Yesintek in Phase 3Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the last six month...
- Biocon shares in focus after subsidiary launches biosimilar alternative to Stelara in the USBiocon Biologics has launched YESINTEK, a biosimilar to Stelara, in the United States for treating chronic autoimmune conditions, offering ...
- Biocon buys back an investor stake in biologics unit, posts Rs 25 crore net profit in Q3FY25Biocon's board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is...
- Biocon shares surge over 4% after Malaysia unit gets clearance from the USFDABiocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated. This followed a...
- Biocon shares zoom 4% as Jefferies upgrades to "hold" amid positive news inflow, sets Rs 400 targetBiocon share price: This upgrade reflects a more positive outlook on the company following recent favorable news flow, particularly concern...
- How is India transforming the global biopharma landscape?In 2024, India's biopharma sector marked notable achievements, with approvals of key biosimilars and the launch of advanced CAR-T therapy. ...
- Biocon Biologics gets US nod to launch Stelara biosimilarBiocon Biologics has secured USFDA approval to launch the biosimilar of Janssen's Stelara by February 2025, targeting autoimmune conditions...
- Biocon settles with Janssen to commercialise biosimilar products in Europe, Canada, JapanBiocon Biologics has entered into a settlement and licence agreement with Janssen Biotech Inc, Janssen Sciences Ireland, and Johnson & John...
- Acceleration of biosimilar business, debt reduction to be key priorties in FY25: Biocon ChiefKiran Mazumdar-Shaw of Biocon aims to consolidate, accelerate biosimilar business, and reduce debt after Viatris acquisition in FY25. Mazum...
- Biocon Biologics inks licence pact with Janssen for biosimilar productThe agreement licenses the company to launch in the US in February 2025, once approved by the US Food and Drug Administration(USFDA), Bioco...
- Aurobindo Pharma subsidiary enters pact with BioFactura for biosimilar ustekinumabCuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma said it has entered into an exclusive license agreement with the US-based ...
- Stocks in news: Cyient DLM, HDFC Bank, Bajaj Auto, Hindustan ZincSuzlon Energy Ltd on Friday said its board has approved a proposal to raise up to Rs 2,000 crore. The company will explore various financia...
- Biocon Biologics may raise additional equity of $300 million in FY24 to pare debtBiocon Biologics plans to raise a further $300m by the end of FY24 in order to reduce its net debt, which peaked at $1.9bn in December 2022...
- Biocon Biologics inks out-licensing agreement with Yoshindo IncUnder the terms of this deal, Japan-based Yoshindo gets exclusive commercialisation rights in Japan for Ustekinumab and Denosumab -- develo...
- Serum Institute invests Rs 4,000 crore towards new plantThis facility would export to about 150 countries and will help increase the company’s market share by 10-15% internationally.
- 'We have a conservative generic policy'Robert Sheroff, president, Global Pharmaceutical Supply Group (GPSG) spoke to Nina Mehta about the company’s plans in the country.
Load More
